DOI: https://doi.org/10.22141/2307-1257.8.1.2019.157794

Renin-angiotensin-aldosterone system blockers as the main pathogenetic approach of drug nephroprotection

N.D. Filipets, D.D. Ivanov, A.I. Gozhenko

Abstract


The paper considers the modern trends in the therapy of nephrologic pathology with nosotropic justification of the predominant role of renin-angiotensin-aldosterone system (RAAS) blockers in modern nephroprotection. The attention is paid to the fact that the pathogenesis of kidney diseases is inevitably associated with the state of RAAS, whose adaptive and compensatory possibilities are naturally changing for pathologic activation and direct involvement, namely, angiotensin II, the main effector molecule, in the structural and functional rebuilding of the kidneys. Pathogenetic therapy is virtually always directed at secondary etiology links, therefore, the modulation of the RAAS state is practically obligatory and is always an effective approach to nephroprotection. Accordingly, suppression of excessive neurohumoral effects at different levels of RAAS is practically relevant, pathogenetically justified mechanism for the preservation of functional nephrons. Administration of drugs with different pharmacodynamic properties depends on the correct selection of patients’ population, the success of therapy — on the adequate selection of RAAS blockers taking into account the clinical situation and their combination with nephroprotectors of other pharmacological classes.

Keywords


renin-angiotensin-aldosterone system blockers; kidneys; pathogenetic therapy; nephroprotection

References


Pyrih LA. The Organization of Nephrological Care in Ukraine: Current Status and Prospects. Počki. 2016;(18):9-11. doi: 10.22141/2307-1257.4.18.2016.84319. (in Ukrainian).

Caravaca-Fontán F, Azevedo L, Luna E, Caravaca F. Patterns of progression of chronic kidney disease at later stages. Clin Kidney J. 2017 Apr;11(2):246-253. doi: 10.1093/ckj/sfx083.

Gozhenko AI, Kuznetsova ES, Kuznetsova EN. Renal functional reserve in patients with type 2 diabetes and chronic kidney disease. Nephrology (Saint-Petersburg). 2015;19(4):95-99. (іn Russian).

Ivanov DD. Central Hemodynamics and Drugs of Choice for the Correction of Hypertension in Chronic Kidney Disease. Počki. 2016;(15):16-21. doi: 10.22141/2307-1257.1.15.2016.71468. (in Ukrainian).

Classification of Diseases of the Urinary System. Ukraïnsʹkij žurnal nefrologìï ta dìalìzu. 2018;(57):4-23. (in Ukrainian).

Liu M, Li XC, Lu L, et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci. 2014;18(19):2918-2926.

Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia. 2016 Nov 7;8(2):56-61. doi: 10.1136/heartasia-2016-010809.

Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018 Feb;16(2):162-177. doi: 10.1016/j.cgh.2017.05.041.

Braam B, Joles JA, Danishwar AH, Gaillard CA. Cardiorenal syndrome-current understanding and future perspectives. Nat Rev Nephrol. 2014 Jan;10(1):48-55. doi: 10.1038/nrneph.2013.250.

Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009 Jul;4(7):1275-83. doi: 10.2215/CJN.02050309.

Christiansen S, Christensen S, Pedersen L, et al. Timing of renal replacement therapy and long-term risk of chronic kidney disease and death in intensive care patients with acute kidney injury. Crit Care. 2017 Dec;21(1):326. doi: 10.1186/s13054-017-1903-y.

Keri KC, Samji NS, Blumenthal S. Diabetic nephropathy: newer therapeutic perspectives. J Community Hosp Intern Med Perspect. 2018 Aug;8(4):200-207. doi: 10.1080/20009666.2018.1500423.

Liang S, Le W, Liang D, et al. Clinico-pathological characteristics and outcomes of patients with biopsy-proven hypertensive nephrosclerosis: a retrospective cohort study. BMC Nephrol. 2016 Apr 11;17:42. doi: 10.1186/s12882-016-0254-2.

Kovesdy CP, Furth SL, Zoccali C; World Kidney Day Steering Committee. Obesity and Kidney Disease: Hidden Consequences of the Epidemic. Can J Kidney Health Dis. J Nephrol. 2017 Feb;30(1):1-10. doi: 10.1007/s40620-017-0377-y.

Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017 Sep;13(9):563-579. doi: 10.1038/nrneph.2017.92.

Bagshaw SM, Darmon M, Ostermann M. Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury. Intensive Care Med. 2017 Jun;43(6):841-854. doi: 10.1007/s00134-017-4762-8.

Zhang F, Liu H, Liu D, et al. Effects of RAAS Inhibitors in Patients with Kidney Disease. Curr Hypertens. 2017Aug;19(9):72. doi: 10.1007/s11906-017-0771-9.

Haltia O, Törmänen S, Eräranta A, et al. Vasopeptidase Inhibition Corrects the Structure and Function of the Small Arteries in Experimental Renal Insufficiency. J Vasc Res. 2015;52(2):94-102. doi: 10.1159/000431368.

Li X, Yang MS. Effects of T-type calcium channel blockers on renal function and aldosterone in patients with hypertension: a systematic review and meta-analysis. PLoS One. 2014 Oct;9(10):e109834. doi: 10.1371/journal.pone.0109834.

Tomiyama H, Yamashina A. Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease. Int J Hypertens. 2014;2014:919256. doi: 10.1155/2014/919256.

Hoshino T, Ookawara S, Miyazawa H, et al. Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. Clin Exp Nephrol. 2015 Apr;19(2):247-253. doi: 10.1007/s10157-014-0981-2.

Takazakura A, Sakurai M, Bando Y, et al. Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy. J Diabetes Invest. 2015 Maу;6(3):346-353. doi: 10.1111/jdi.12296.

Vargas-Santos AB, Neogi T. Management of Gout and Hyperuricemia in CKD. Am J Kidney Dis. 2017 Sep;70(3):422-439. doi: 10.1053/j.ajkd.2017.01.055.

Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2017 Jun;10:135-143. doi: 10.2147/IJNRD.S105771.

Al-Waili N, Al-Waili H, Al-Waili T, Salom K. Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials. Redox Rep. 2017 Maу;22(3):99-118. doi: 10.1080/13510002.2017.1297885.

Suki WN, Moore LW. Phosphorus Regulation in Chronic Kidney Disease. Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4 Suppl):6-9. doi: 10.14797/mdcj-12-4s1-6.

Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007 Sep;59(3):251-287. doi: 10.1124/pr.59.3.3.

Ivanov DD. Renin-angiotensin system antagonists, glomerular filtration rate and blood pressure. Počki. 2018;7(1):6-10. doi: 10.22141/2307-1257.7.1.2018.122214. (in Ukrainian).

Gozhenko АI. Pathogenesis of toxic nephropathy. Actual problems of transport medicine. 2006;(4):9-15. (in Russian).

Tufro A, Veron D. VEGF and podocytes in diabetic nephropathy. Semin Nephrol. 2012 Jul;32(4):385-393. doi: 10.1016/j.semnephrol.2012.06.010.

Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009 Feb;19(2):156-172. doi: 10.1038/cr.2009.5.

Xu Z, Li W, Han J, et al. Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2). Sci Rep. 2017 Mar;7:44911. doi: 10.1038/srep44911.

Zhang F, Liu H, Liu D, et al. Effects of RAAS Inhibitors in Patients with Kidney Disease. Curr Hypertens Rep. 2017 Aug;19(9):72. doi: 10.1007/s11906-017-0771-9.

Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag. 2011;7:749-59. doi: 10.2147/VHRM.S22591.

Agrawal A, Kamila S, Reddy S, Lilly J, Mariyala MS. Effect of telmisartan on kidney function in patients with chronic kidney disease: an observational study. J Drug Assess. 2016;5(1):24-28. doi: 10.1080/21556660.2016.1252380.

Wang T, Takabatake T. Effects of Vasopeptidase Inhibition on Renal Function and Tubuloglomerular Feedback in Spontaneously Hypertensive Rats. Hypertens Res. 2005 Jul;28(7):611-618. doi: 10.1291/hypres.28.611.

Davidson EP, Coppey LJ, Holmes A, Dake B, Yorek MA. Effect of treatment of high fat fed/low dose streptozocin-diabetic rats with Ilepatril on vascular and neural complications. Eur J Pharmacol. 2011 Oct 15;668(3):497-506. doi: 10.1016/j.ejphar.2011.07.016.

Velkoska E, Dean RG, Burchill L, Levidiotis V, Burrell LM. Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin Sci (Lond). 2010 Feb;118(4):269-279. doi: 10.1042/CS20090318.

Zanchi A, Maillard M, Burnier M. Recent clinical trials with omapatrilat: new developments. Curr Hypertens Rep. 2003;5(4):346-352.

Sen S, Sabırlı S, Özyiğit T, Üresin Y. Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. Ther Adv Chronic Dis. 2013 Sep;4(5):232-241. doi: 10.1177/2040622313495288.

Chen H, Sun F, Zhong X, Shao Y, Yoshimura A, Liu Y. Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res. 2013;37(6):557-566. doi: 10.1159/000355736.

Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013 Oct;62(17):1585-1593. doi: 10.1016/j.jacc.2013.04.086.

Peti-Peterdi J, Harris RC. Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol. 2010 Jul;21(7):1093-6. doi: 10.1681/ASN.2009070759.

Hozhenko AІ, Kravchuk AV, Nikitenko OP, Moskolenko OM, Sirman VM. Funktsіonal'nii nirkovii rezerv: Monografіia [Renal functional reserve: Monograph]. Odesa: Feniks; 2015. 180 p. (in Ukrainian).

Ivanov DD, Kuryata OV, Garmysh IP. Renin angiotensin-aldosterone system blockers: chronic kidney disease and cardiovascular risk. Počki. 2018;7(2):81-90. doi: 10.22141/2307- 1257.7.2.2018.127393.






Copyright (c) 2019 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта